-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-09-12
The reference study develops a nonviral, localized tumor-suppressor replacement strategy using chemically modified p21 mRNA in lipid nanoparticles for bladder cancer. Its preclinical data connect bladder-restricted expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression, while also highlighting the translational limits of moving from an orthotopic mouse model to clinical therapy.
-
DMXAA in Nuclear-Targeted Nanorods for STING Immunity
2026-09-11
The reference study develops PFPD, self-assembled peptide nanorods that co-deliver DMXAA and a photosensitizer to tumor-cell nuclei. Light-triggered nuclear DNA damage supplies endogenous immunostimulatory DNA, while DMXAA activates STING, producing stronger innate immune responses and suppressing lung metastatic tumors in experimental models.
-
Gefitinib as an EGFR Signaling Probe
2026-09-11
Explore how Gefitinib (ZD1839) can function as a causal EGFR signaling probe in cancer and blue-light skin-barrier assays. This guide connects molecular pharmacology, pathway-resolved readouts, and practical experimental design while clearly separating established evidence from translational hypotheses.
-
TRIM21–ERK1/2 Signaling in Pituitary Adenomas
2026-09-10
The reference study identifies TRIM21 as a regulator of ERK1/2 signaling, pituitary adenoma cell proliferation, and resistance to dopamine-directed therapy. Its combination of CRISPR screening, biochemical validation, animal models, and NanoBiT-based drug screening nominates TRIM21 suppression as a mechanistically testable treatment strategy.
-
Mechanisms of Cell Death in Heart Disease
2026-09-10
This review reframes necrosis as potentially regulated rather than uniformly passive, placing apoptosis, necrosis, and autophagy within interconnected death-signaling networks relevant to myocardial infarction and heart failure. Its practical value lies in showing why morphology, ATP status, membrane integrity, and pathway-specific perturbations should be interpreted together when designing cell-death studies.
-
MK-5108 (VX-689): Assay Workflows
2026-09-09
A scenario-driven guide to using MK-5108 (VX-689), SKU A4120, in Aurora-A-focused viability, proliferation, and cytotoxicity studies. It connects biochemical selectivity, formulation handling, dose-response design, retinoblastoma evidence, and practical vendor selection to improve assay interpretability.
-
Spermine as a Mechanistic Cell Biology Probe
2026-09-09
Spermine is an endogenous polyamine that links ion channel regulation with experimental analysis of membrane biology. This article explains how its defined inward rectifier activity can sharpen assay design while clarifying what the CLCC1 herpesvirus nuclear-egress study does—and does not—demonstrate.
-
Go 6983: Pan-PKC Inhibitor Research Guide
2026-09-08
Go 6983 is a pan-PKC inhibitor used to dissect isoform-dependent PKC signaling in cancer, EMT, and cellular assays. Its strongest reported biochemical activity is against PKCα, PKCβ, PKCγ, and PKCδ, while PKCμ is substantially less sensitive according to product information.
-
Resiquimod (R-848): Designing Better Ablation Assays
2026-09-08
Resiquimod (R-848) is a dual TLR7/8 agonist that can reveal how innate immune response modulation shapes post-ablation tumor biology. This guide presents a spatial, time-resolved framework for connecting TLR signaling, thermal injury, drug release, and translational assay design.
-
Gramine, CUL3–MTDH, and Ferroptosis in TNBC
2026-09-07
A 2026 study identifies gramine as a selective inhibitor of triple-negative breast cancer and connects its activity to CUL3-dependent control of MTDH and ferroptosis. Its combination of chemical screening, target-engagement assays, genetic rescue, and xenograft validation provides a useful framework for evaluating mechanism rather than relying on pathway correlation alone.
-
Decitabine Priming Strengthens Anti–PD-1 Immunity
2026-09-05
The reference study shows that low-dose decitabine can improve anti–PD-1 therapy by expanding and preserving CD8+ progenitor exhausted T cells rather than simply increasing short-term T-cell activation. Its mechanistic findings implicate sustained JunD and JNK/AP-1 activity, offering a rationale for combining epigenetic priming with checkpoint blockade while highlighting the need for careful tumor-model validation.
-
Mifepristone (RU486) in Integrated Cell Assays
2026-09-05
Mifepristone (RU486) is more than a progesterone receptor antagonist: it can serve as a mechanistic perturbation in integrated oncology, reproductive, and safety assays. This guide connects its pathway biology with transcriptomic and functional testing strategies inspired by human iPSC-derived cardiomyocyte research.
-
BOP Reagent for Prodrug Coupling Workflows
2026-09-04
BOP reagent provides an organic-phase route to carboxyl group activation, amide bond formation, phenyl ester preparation, and linker assembly. This guide connects practical coupling controls with the carrier-free, ROS-responsive triterpene prodrug strategy reported for oral squamous cell carcinoma research, while distinguishing published findings from workflow recommendations.
-
IGFBP2–THBS1 Axis in GH-Mediated Bone Growth
2026-09-04
This study identifies an IGFBP2–THBS1 regulatory axis that connects growth hormone treatment with IGF-1 signaling, chondrocyte proliferation, and hypertrophic differentiation in idiopathic short stature. Its combination of patient plasma data, bioinformatic prediction, and gain- and loss-of-function experiments provides a mechanistic framework for interpreting variable responses to GH therapy, while also highlighting the limits of extrapolating cell-based findings to clinical growth outcomes.
-
A 83-01 for Intestinal Organoid Assays
2026-09-03
Explore how A 83-01, a selective ALK-5 inhibitor, can add mechanistic resolution to human iPSC-derived intestinal organoid assays. This guide connects TGF-β pathway perturbation with epithelial maturation, transporter activity, and CYP3A-mediated pharmacokinetic readouts while separating established findings from practical recommendations.